• Pediatric patients with LCH with BRAFV600E PBMC at diagnosis are at highest risk of treatment failure and LCH-associated neurodegeneration.

  • We propose a shift from survival-based staging to risk of treatment failure based on extent of disease and peripheral BRAFV600E PBMC.

Abstract

Langerhans cell histiocytosis (LCH) is a myeloid neoplastic disorder driven by mitogen-activated protein kinase (MAPK) activation in hematopoietic cells. Historically, LCH has been staged according to involvement of “risk organs” (bone marrow, liver, and spleen), based on risk of death. With improvements in supportive care and efficacy of MAPK pathway inhibitors, patients with LCH now rarely die. However, most patients with LCH with multisystem disease are not cured with current front-line chemotherapy, and treatment failure is associated with long-term morbidity, including LCH-associated neurodegeneration (LCH-ND). In this study, we evaluated the impact of extent of LCH at presentation, tumor genotype, and BRAFV600E in pretherapy peripheral blood mononuclear cells (PBMCs) and bone marrow on systemic and central nervous system outcomes in a cohort of 385 pediatric patients with LCH and 115 adults with LCH, followed up for a median of 4 years (range, 0.02-18 years). Five-year event-free survival was 50.7% for pediatric patients and 32.7% for adult patients with LCH. In the pediatric cohort, presence of BRAFV600E PBMC was strongly associated with front-line treatment failure (hazard ratio [HR], 7.7). Remarkably, BRAFV600E PBMC at diagnosis also identified patients at the highest risk of developing LCH-ND (HR, 23.1). These findings support an updated model of pediatric LCH pathogenesis in which persistence of disease reservoir and cell of origin determine extent of disease and clinical risks. We, therefore, propose a major revision of pediatric LCH diagnostic staging, shifting from focus on historical risk of death to risks of systemic treatment failure and LCH-ND based on lesion location, lesion genotype, and peripheral LCH reservoir (eg, BRAFV600E PBMC).

1.
Khoury
JD
,
Solary
E
,
Abla
O
, et al
.
The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms
.
Leukemia
.
2022
;
36
(
7
):
1703
-
1719
.
2.
Picarsic
J
,
Jaffe
R
.
Nosology and pathology of Langerhans cell histiocytosis
.
Hematol Oncol Clin North Am
.
2015
;
29
(
5
):
799
-
823
.
3.
Stålemark
H
,
Laurencikas
E
,
Karis
J
,
Gavhed
D
,
Fadeel
B
,
Henter
JI
.
Incidence of Langerhans cell histiocytosis in children: a population-based study
.
Pediatr Blood Cancer
.
2008
;
51
(
1
):
76
-
81
.
4.
Allen
CE
,
Merad
M
,
McClain
KL
.
Langerhans-cell histiocytosis
.
N Engl J Med
.
2018
;
379
(
9
):
856
-
868
.
5.
Bielamowicz
K
,
Dimitrion
P
,
Abla
O
, et al;
North American Consortium for Histiocytosis
.
Langerhans cell histiocytosis: NACHO update on progress, chaos, and opportunity on the path to rational cures
.
Cancer
.
2024
;
130
(
14
):
2416
-
2439
.
6.
Badalian-Very
G
,
Vergilio
JA
,
Degar
BA
, et al
.
Recurrent BRAF mutations in Langerhans cell histiocytosis
.
Blood
.
2010
;
116
(
11
):
1919
-
1923
.
7.
Diamond
EL
,
Durham
BH
,
Haroche
J
, et al
.
Diverse and targetable kinase alterations drive histiocytic neoplasms
.
Cancer Discov
.
2016
;
6
(
2
):
154
-
165
.
8.
Chakraborty
R
,
Burke
TM
,
Hampton
OA
, et al
.
Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis
.
Blood
.
2016
;
128
(
21
):
2533
-
2537
.
9.
McClain
KL
,
Bigenwald
C
,
Collin
M
, et al
.
Histiocytic disorders
.
Nat Rev Dis Primers
.
2021
;
7
(
1
):
73
.
10.
Berres
ML
,
Lim
KP
,
Peters
T
, et al
.
BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups
.
J Exp Med
.
2014
;
211
(
4
):
669
-
683
.
11.
Héritier
S
,
Emile
JF
,
Barkaoui
MA
, et al
.
BRAF mutation correlates with high-risk Langerhans cell histiocytosis and increased resistance to first-line therapy
.
J Clin Oncol
.
2016
;
34
(
25
):
3023
-
3030
.
12.
Kemps
PG
,
van den Bos
C
,
van Halteren
AGS
;
International Study Group
.
Clinical associations of BRAF and MAP2K1 mutations in pediatric Langerhans cell histiocytosis: when 1 + 1 = 3
.
Am J Hematol
.
2023
;
98
(
9
):
E244
-
E246
.
13.
Héritier
S
,
Barkaoui
MA
,
Miron
J
, et al
.
Incidence and risk factors for clinical neurodegenerative Langerhans cell histiocytosis: a longitudinal cohort study
.
Br J Haematol
.
2018
;
183
(
4
):
608
-
617
.
14.
McClain
KL
,
Picarsic
J
,
Chakraborty
R
, et al
.
CNS Langerhans cell histiocytosis: common hematopoietic origin for LCH-associated neurodegeneration and mass lesions
.
Cancer
.
2018
;
124
(
12
):
2607
-
2620
.
15.
Gadner
H
,
Grois
N
,
Pötschger
U
, et al;
Histiocyte Society
.
Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification
.
Blood
.
2008
;
111
(
5
):
2556
-
2562
.
16.
Yeh
EA
,
Greenberg
J
,
Abla
O
, et al
.
Evaluation and treatment of Langerhans cell histiocytosis patients with central nervous system abnormalities: current views and new vistas
.
Pediatr Blood Cancer
.
2018
;
65
(
1
):
10.1002
.
17.
Berres
ML
,
Allen
CE
,
Merad
M
.
Pathological consequence of misguided dendritic cell differentiation in histiocytic diseases
.
Adv Immunol
.
2013
;
120
:
127
-
161
.
18.
Haupt
R
,
Minkov
M
,
Astigarraga
I
, et al
.
Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years
.
Pediatr Blood Cancer
.
2013
;
60
(
2
):
175
-
184
.
19.
Grois
N
,
Fahrner
B
,
Arceci
RJ
, et al;
Histiocyte Society CNS LCH Study Group
.
Central nervous system disease in Langerhans cell histiocytosis
.
J Pediatr
.
2010
;
156
(
6
):
873
-
881.e1
. PMID: 20434166.
20.
Chakraborty
R
,
Hampton
OA
,
Shen
X
, et al
.
Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis
.
Blood
.
2014
;
124
(
19
):
3007
-
3015
.
21.
Scollon
S
,
Eldomery
MK
,
Reuther
J
, et al
.
Clinical and molecular features of pediatric cancer patients with Lynch syndrome
.
Pediatr Blood Cancer
.
2022
;
69
(
11
):
e29859
.
22.
Ballester
LY
,
Cantu
MD
,
Lim
KPH
, et al
.
The use of BRAF V600E mutation-specific immunohistochemistry in pediatric Langerhans cell histiocytosis
.
Hematol Oncol
.
2018
;
36
(
1
):
307
-
315
.
23.
Milne
P
,
Abhyankar
H
,
Scull
B
, et al
.
Cellular distribution of mutations and association with disease risk in Langerhans cell histiocytosis without BRAFV600E
.
Blood Adv
.
2022
;
6
(
16
):
4901
-
4904
.
24.
Kemps
PG
,
Zondag
TCE
,
Arnardóttir
HB
, et al
.
Clinicogenomic associations in childhood Langerhans cell histiocytosis: an international cohort study
.
Blood Adv
.
2023
;
7
(
4
):
664
-
679
.
25.
Minkov
M
,
Steiner
M
,
Pötschger
U
,
Aricò
M
,
Braier
J
,
Donadieu
J
,
Grois
N
,
Henter
JI
,
Janka
G
,
McClain
K
,
Weitzman
S
,
Windebank
K
,
Ladisch
S
,
Gadner
H
;
International LCH Study Group
International LCH Study Group
.
Reactivations in multisystem Langerhans cell histiocytosis: data of the international LCH registry
.
J Pediatr
.
2008
;
153
(
5
):
700
-
705.e7052
.
26.
Toogood
IRG
,
Ellis
WM
,
Ekert
H
.
Prognostic criteria, treatment and survival in disseminated histiocytosis X
.
Aust Paediatr J
.
1979
;
15
(
2
):
91
-
95
.
27.
Nezelof
C
,
Frileux-Herbet
F
,
Cronier-Sachot
J
.
Disseminated histiocytosis X: analysis of prognostic factors based on a retrospective study of 50 cases
.
Cancer
.
1979
;
44
(
5
):
1824
-
1838
.
28.
Braier
J
,
Chantada
G
,
Rosso
D
, et al
.
Langerhans cell histiocytosis: retrospective evaluation of 123 patients at a single institution
.
Pediatr Hematol Oncol
.
1999
;
16
(
5
):
377
-
385
.
29.
Lucaya
J
.
Histiocytosis X
.
Am J Dis Child
.
1971
;
121
:
289
-
295
.
30.
Lahey
E
.
Histiocytosis x--an analysis of prognostic factors
.
J Pediatr
.
1975
;
87
(
2
):
184
-
189
.
31.
Goyal
G
,
Shah
MV
,
Hook
CC
, et al
.
Adult disseminated Langerhans cell histiocytosis: incidence, racial disparities and long-term outcomes
.
Br J Haematol
.
2018
;
182
(
4
):
579
-
581
.
32.
Ribeiro
KB
,
Degar
B
,
Antoneli
CBG
,
Rollins
B
,
Rodriguez-Galindo
C
.
Ethnicity, race, and socioeconomic status influence incidence of Langerhans cell histiocytosis
.
Pediatr Blood Cancer
.
2015
;
62
(
6
):
982
-
987
.
33.
Donadieu
J
,
Larabi
IA
,
Tardieu
M
, et al
.
Vemurafenib for refractory multisystem Langerhans cell histiocytosis in children: an international observational study
.
J Clin Oncol
.
2019
;
37
(
31
):
2857
-
2865
.
34.
Eckstein
OS
,
Visser
J
,
Rodriguez-Galindo
C
,
Allen
CE
;
NACHO-LIBRE Study Group
.
Clinical responses and persistent BRAF V600E(+) blood cells in children with LCH treated with MAPK pathway inhibition
.
Blood
.
2019
;
133
(
15
):
1691
-
1694
.
35.
Cournoyer
E
,
Ferrell
J
,
Sharp
S
, et al
.
Dabrafenib and trametinib in Langerhans cell histiocytosis and other histiocytic disorders
.
Haematologica
.
2024
;
109
(
4
):
1137
-
1148
.
36.
Rigaud
C
,
Barkaoui
MA
,
Thomas
C
, et al
.
Langerhans cell histiocytosis: therapeutic strategy and outcome in a 30-year nationwide cohort of 1478 patients under 18 years of age
.
Br J Haematol
.
2016
;
174
(
6
):
887
-
898
.
37.
Chow
TW
,
Leung
WK
,
Cheng
FWT
, et al
.
Late outcomes in children with Langerhans cell histiocytosis
.
Arch Dis Child
.
2017
;
102
(
9
):
830
-
835
.
38.
Gadner
H
,
Minkov
M
,
Grois
N
, et al;
Histiocyte Society
.
Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis
.
Blood
.
2013
;
121
(
25
):
5006
-
5014
.
39.
Haupt
R
,
Nanduri
V
,
Calevo
MG
, et al
.
Permanent consequences in Langerhans cell histiocytosis patients: a pilot study from the Histiocyte Society-Late Effects Study Group
.
Pediatr Blood Cancer
.
2004
;
42
(
5
):
438
-
444
.
40.
Wilk
CM
,
Cathomas
F
,
Torok
O
, et al
.
Circulating senescent myeloid cells infiltrate the brain and cause neurodegeneration in histiocytic disorders
.
Immunity
.
2023
;
56
(
12
):
2790
-
2802.e6
.
41.
Kudo
K
,
Toki
T
,
Kanezaki
R
, et al
.
BRAF V600E-positive cells as molecular markers of bone marrow disease in pediatric Langerhans cell histiocytosis
.
Haematologica
.
2022
;
107
(
7
):
1719
-
1725
.
42.
Hyman
DM
,
Diamond
EL
,
Vibat
CR
, et al
.
Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders
.
Cancer Discov
.
2015
;
5
(
1
):
64
-
71
.
43.
Héritier
S
,
Hélias-Rodzewicz
Z
,
Lapillonne
H
, et al
.
Circulating cell-free BRAFV600E as a biomarker in children with Langerhans cell histiocytosis
.
Br J Haematol
.
2017
;
178
(
3
):
457
-
467
.
44.
Papo
M
,
Diamond
EL
,
Cohen-Aubart
F
, et al
.
High prevalence of myeloid neoplasms in adults with non-Langerhans cell histiocytosis
.
Blood
.
2017
;
130
(
8
):
1007
-
1013
.
45.
Parekh
D
,
Lin
H
,
Batajoo
A
, et al
.
Clofarabine monotherapy in aggressive, relapsed and refractory Langerhans cell histiocytosis
.
Br J Haematol
.
2024
;
204
(
5
):
1888
-
1893
.
46.
Karri
V
,
Lin
H
,
Velazquez
J
, et al
.
Clinical, radiological and molecular responses to combination chemotherapy with MAPK pathway inhibition in relapsed and refractory Langerhans cell histiocytosis
.
Br J Haematol
.
2024
;
204
(
5
):
1882
-
1887
.
You do not currently have access to this content.
Sign in via your Institution